dc.contributor.author |
Sheikuduman, Thattakudian |
|
dc.contributor.author |
Jyothi, Kakavakam |
|
dc.contributor.author |
Babu, S Chandra |
|
dc.contributor.author |
Saleem, Mohamed |
|
dc.date.accessioned |
2022-12-15T04:05:36Z |
|
dc.date.available |
2022-12-15T04:05:36Z |
|
dc.date.issued |
2019-01-31 |
|
dc.identifier.citation |
Saleem, T. S. M., Jyothi, K., & Babu, S. C. (2019). A case report on Nevirapine induced exfoliative dermatitis. Pakistan Journal of Pharmaceutical Sciences, 32(1). |
en_US |
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/15089 |
|
dc.description.abstract |
Drug induced adverse drug reactions is more common in long term therapy particularly in immune
compromised patients. Most of the drugs causing dermatological reactions like skin rashes, pruritus, steven johnson syndrome and exfoliative dermatitis. Nevirapine is the first line drug for human immunodeficiency virus (HIV) infection from the category of non-nucleoside reverse transcriptase enzyme inhibitor (NNRTI). In the present cases, we have reported the nevirapine induced severe exfoliative dermatitis. A patient admitted in the hospital with the symptoms of scaling on the skin and he received Nevirapine as a drug for his diagnosis of HIV for past three years. After clear examination exfoliative dermatitis was conformed and suspected with the cause due to Nevirapine. The drug was stopped and the patient was treated with drugs for symptomatic cure. The patient was recovered from his condition and other antiretroviral drugs were recommended for his treatment. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi |
en_US |
dc.subject |
Antiretroviral therapy |
en_US |
dc.subject |
adverse drug reaction |
en_US |
dc.subject |
erythroderma |
en_US |
dc.subject |
HIV |
en_US |
dc.subject |
skin rashes |
en_US |
dc.title |
REPORT A case report on Nevirapine induced exfoliative dermatitis |
en_US |
dc.type |
Article |
en_US |